Pathways Neuro Pharma Inc.

Pathways Neuro Pharma is advancing next-generation gene therapies for Juvenile Parkinson’s Disease and other rare neurological disorders. • Utilizing the AAV6.2FF gene therapy platform, a clinically validated delivery vector capable of CNS-wide transduction through intrathecal or intracisternal magna administration—supporting long-acting, single-administration treatments with expression durability exceeding 12 months in preclinical models. • Our lead program targets mitochondrial dysfunction and impaired cellular repair, aiming to slow or halt neurodegeneration and offer a potentially disease-modifying therapy for pediatric patients. • A second program is designed to restore dopaminergic tone without direct receptor stimulation—offering a new therapeutic option for children with movement disorders and minimizing the complications of chronic L-dopa exposure. • We are also pioneering targeted modulation of neurotransmitter systems involved in cognitive and behavioral regulation, using gene-based approaches to rebalance dopamine and serotonin signaling through endogenous pathways. • Across our pipeline, Pathways is committed to reducing treatment burden and enhancing adherence through durable, CNS-directed gene therapies that bring new hope to families affected by devastating brain diseases.